摘要 :
Abstract One out of ten patients with Philadelphia‐negative myeloproliferative neoplasms (MPN) develop a second cancer (SC): in such patients we aimed at assessing the survival impact of SC itself and of MPN‐specific therapies. ...
展开
Abstract One out of ten patients with Philadelphia‐negative myeloproliferative neoplasms (MPN) develop a second cancer (SC): in such patients we aimed at assessing the survival impact of SC itself and of MPN‐specific therapies. Data were therefore extracted from an international nested case‐control study, recruiting 798 patients with SC diagnosed concurrently or after the MPN. Overall, 2995 person‐years (PYs) were accumulated and mortality rate (MR) since SC diagnosis was 5.9 (5.1‐6.9) deaths for every 100 PYs. A “poor prognosis” SC (stomach, esophagus, liver, pancreas, lung, ovary, head‐and‐neck or nervous system, osteosarcomas, multiple myeloma, aggressive lymphoma, acute leukemia) was reported in 26.3% of the patients and was the cause of death in 65% of them (MR 11.0/100 PYs). In contrast, patients with a “non‐poor prognosis” SC (NPPSC) incurred a MR of 4.6/100 PYs: 31% of the deaths were attributed to SC and 15% to MPN evolution. At multivariable analysis, death after SC diagnosis was independently predicted (HR and 95% CI) by patient age greater than 70?years (2.68; 1.88‐3.81), the SC prognostic group (2.57; 1.86‐3.55), SC relapse (1.53; 10.6‐2.21), MPN evolution (2.72; 1.84‐4.02), anemia at SC diagnosis (2.32; 1.49‐3.59), exposure to hydroxyurea (1.89; 1.26‐2.85) and to ruxolitinib (3.63; 1.97‐6.71). Aspirin was protective for patients with a NPPSC (0.60; 0.38‐0.95). In conclusion, SC is a relevant cause of death competing with MPN evolution. Prospective data are awaited to confirm the role of cytoreductive and anti‐platelet drugs in modulating patient survival after the occurrence of a SC.
收起
摘要 :
Abstract Biological sample collection is becoming more common in epidemiology research to obtain DNA for genetic analysis. There are many different DNA collection methods but little evidence on their relative effectiveness. Theref...
展开
Abstract Biological sample collection is becoming more common in epidemiology research to obtain DNA for genetic analysis. There are many different DNA collection methods but little evidence on their relative effectiveness. Therefore, we took the opportunity of a prospective case‐control study in myeloproliferative neoplasms (MPNs) to compare DNA yield from 8.5 mL PAXgene tubes for whole blood collection versus 2 mL Oragene OG‐500 saliva collection kits. MPNs include polycythaemia vera, essential thrombocythaemia, and primary myelofibrosis. These are rare diseases and our exploratory case–control study (MOSAICC) sought to improve knowledge regarding their aetiology and to determine optimal methodology for a larger UK‐wide study. Overall, 233 participants were recruited to the MOSIACC study, and we collected 187 blood and 214 saliva samples. The mean DNA yield from blood was 659.18 ng/μL, significantly higher than the mean DNA yield from saliva samples (275.79 ng/μL). The higher provision of saliva samples might reflect its non‐invasive and more convenient nature, compared to blood sample provision. The differences in mean DNA yields might reflect differences in clinical assistance, adherence to instructions, and health status of individuals. In conclusion, both sample collection techniques are simple, effective, and suitable for DNA collection for genetic analysis in future epidemiological research studies but OG‐500 kits offer a less invasive alternative for those who refuse to provide blood.
收起
原文获取